Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels

Thromb Res. 2022 Jul:215:1-4. doi: 10.1016/j.thromres.2022.05.005. Epub 2022 May 13.

Authors

Siraj Mithoowani¹, Karen A Moffat², Akash Gupta³, Stephen A Carlino⁴, Mark A Crowther⁵

Affiliations

¹ Department of Medicine, McMaster University, Hamilton, Canada.
² Department of Medicine, McMaster University, Hamilton, Canada; Hamilton Regional Laboratory Medicine Program, Hamilton, Canada.
³ Department of Pathology and Molecular Medicine, Hamilton, Canada.
⁴ Hamilton Regional Laboratory Medicine Program, Hamilton, Canada.
⁵ Department of Medicine, McMaster University, Hamilton, Canada. Electronic address: [email protected].

PMID: 35580465
DOI: 10.1016/j.thromres.2022.05.005

No abstract available

Keywords: Anticoagulant reversal; Anticoagulants; Blood coagulation tests; Factor Xa inhibitors.

Publication types

Letter

MeSH terms

Administration, Oral
Anticoagulants / pharmacology
Anticoagulants / therapeutic use
Blood Coagulation Tests
Factor Xa Inhibitors / pharmacology
Factor Xa Inhibitors / therapeutic use
Heparin, Low-Molecular-Weight / pharmacology
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Pyrazoles / pharmacology
Pyrazoles / therapeutic use
Pyridones* / pharmacology
Pyridones* / therapeutic use
Rivaroxaban* / pharmacology
Rivaroxaban* / therapeutic use

Substances

Anticoagulants
Factor Xa Inhibitors
Heparin, Low-Molecular-Weight
Pyrazoles
Pyridones
apixaban
Rivaroxaban